Acurx Pharmaceuticals (ACXP) Net Cash Flow (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Net Cash Flow came in at $1.7 million in Q1 2026, up 81.26% YoY from $937174.0 in Q1 2025, and up 3.0% on a QoQ basis from $1.6 million in Q4 2025.
Acurx Pharmaceuticals (ACXP) Net Cash Flow (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Net Cash Flow data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Net Cash Flow rose 81.26% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (up 207.81% YoY) and the FY2025 annual result came in at $3.8 million, up 202.17% from the prior year.
- Net Cash Flow grew to $1.7 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $1.7 million in Q1 2026 to a low of -$2.6 million in Q2 2024.
- A 5-year average of -$643700.8 and a median of -$1.5 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow sank 587.33% — and 2025, when it surged 180.22%.
- Tracing ACXP's Net Cash Flow over 5 years: stood at -$1.5 million in 2022, then soared by 128.21% to $421859.0 in 2023, then slumped by 587.33% to -$2.1 million in 2024, then jumped by 180.22% to $1.6 million in 2025, then climbed by 3.0% to $1.7 million in 2026.
- The last three Net Cash Flow figures came in at $1.7 million (Q1 2026), $1.6 million (Q4 2025), and -$157326.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | 1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Mn |
| Jun 30, 2026 | 1.40 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Sep 30, 2025 | -157,326.00 |
| Sep 30, 2025 | -157,326.00 |
| Jun 30, 2025 | 1.42 Mn |
| Jun 30, 2025 | 1.42 Mn |
| Mar 31, 2025 | 937,174.00 |
| Mar 31, 2025 | 937,174.00 |
| Dec 31, 2024 | -2.06 Mn |
| Dec 31, 2024 | -2.06 Mn |
| Sep 30, 2024 | -598,294.00 |
| Sep 30, 2024 | -598,294.00 |
| Jun 30, 2024 | -2.56 Mn |
| Jun 30, 2024 | -2.56 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.45 Mn |